CTOs on the Move

Radioisotope Life Sciences

www.rls.bio

 
RLS (Radioisotope Life Sciences), the third-largest nuclear medicine pharmacy network in the United States, owns and operates 31 radiopharmacies across 18 states, offering an extensive portfolio of molecular imaging products. We endeavor to supply the highest quality radiopharmaceuticals in the industry by dispensing 100 percent of injectable unit dose products in clean rooms built to ISO 1644-1 specifications. In support of our commitment to quality, we provide tailored solutions and exceptional service to our more than 1500 customers.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.rls.bio
  • 801 International Parkway Suite 5092
    Lake Mary, FL USA 32746
  • Phone: 813.285.3065

Executives

Name Title Contact Details

Similar Companies

Advanced Accelerator Applications

Advanced Accelerator Applications is a pharmaceutical group specialized in the field of nuclear medicine.

Maag Prescription

Maag Prescription is a Pocatello, ID-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Signature Health

At Signature Health, we treat the mind and body with an integrated approach to health care. We offer mental health, primary care, and addiction recovery services.

Cychem

Cychem is a Thousand Oaks, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Dragon Pharmaceuticals

Dragon Pharmaceuticals Inc. (OTC-BB: Drug) is an international biotech company headquartered in Vancouver, Canada, with production and R&D facilities in Nanjing, China and 160 employees worldwide. The Company develops and commercializes human proteins for therapeutic use. Using superior and proprietary DNA vector technology, Dragon is able to produce high yields of quality protein drugs at low costs and high margins. Dragon is one of the world`s largest producers of Epoetin Alfa, or EPO, a therapeutic protein used to treat anemia related to kidney failure, chemotherapy, and surgery. Dragon`s EPO is approved and being marketed for use in chronic renal failure in China, Egypt, India and Peru. Additional regulatory submissions are in progress throughout Central and Eastern Europe, Southeast Asia, Latin America and the Middle East.